Completed
PHASE2
INTERVENTIONAL
NCT00166725
Effects of Octreotide Acetate on Circulating Levels of Chromogranin A in Advanced Prostate Cancer Patients
View on ClinicalTrials.gov
Updated Dec 15, 2025
Brief Summary
The present study will provide information on whether the somatostatin analog, octreotide acetate, could have an inhibitory effect on circulating chromogranin A. The demonstration of an antisecretory effect of somatostatin analogs could offer a rationale for a large scale randomized study.
Interventions
Name:
Octreotide LAR
Type:
DRUG
Description:
Primary Outcomes
Measure:
Time to 25% decrease in chromogranin A plasma level (evaluation every 4 weeks for the first 12 weeks and every 12 weeks after)
TimeFrame:
Description:
Trial Information
NCT ID
NCT00166725
Status
Completed
Study Type
INTERVENTIONAL
Phases
PHASE2
Sponsor
Novartis
Last Updated
December 15, 2025